BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Donisi C, Puzzoni M, Ziranu P, Lai E, Mariani S, Saba G, Impera V, Dubois M, Persano M, Migliari M, Pretta A, Liscia N, Astara G, Scartozzi M. Immune Checkpoint Inhibitors in the Treatment of HCC. Front Oncol 2020;10:601240. [PMID: 33585218 DOI: 10.3389/fonc.2020.601240] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Wei L, Wang Z, Jing N, Lu Y, Yang J, Xiao H, Guo H, Sun S, Li M, Zhao D, Li X, Qi W, Zhang Y. Frontier progress of the combination of modern medicine and traditional Chinese medicine in the treatment of hepatocellular carcinoma. Chin Med 2022;17:90. [PMID: 35907976 DOI: 10.1186/s13020-022-00645-0] [Reference Citation Analysis]
2 Spanu D, Pretta A, Lai E, Persano M, Donisi C, Mariani S, Dubois M, Migliari M, Saba G, Ziranu P, Pusceddu V, Puzzoni M, Astara G, Scartozzi M. Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment. World J Hepatol 2022; 14(7): 1319-1332 [DOI: 10.4254/wjh.v14.i7.1319] [Reference Citation Analysis]
3 Pérez-López A, Martín-Sabroso C, Gómez-Lázaro L, Torres-Suárez AI, Aparicio-Blanco J. Embolization therapy with microspheres for the treatment of liver cancer: State-of-the-art of clinical translation. Acta Biomater 2022:S1742-7061(22)00412-3. [PMID: 35842035 DOI: 10.1016/j.actbio.2022.07.019] [Reference Citation Analysis]
4 Wang S, Wu Y, Liu M, Zhao Q, Jian L. DHW-208, A Novel Phosphatidylinositol 3-Kinase (PI3K) Inhibitor, Has Anti-Hepatocellular Carcinoma Activity Through Promoting Apoptosis and Inhibiting Angiogenesis. Front Oncol 2022;12:955729. [DOI: 10.3389/fonc.2022.955729] [Reference Citation Analysis]
5 Jiang Y, Luo K, Xu J, Shen X, Gao Y, Fu W, Zhang X, Wang H, Liu B. Integrated Analysis Revealing the Senescence-Mediated Immune Heterogeneity of HCC and Construction of a Prognostic Model Based on Senescence-Related Non-Coding RNA Network. Front Oncol 2022;12:912537. [DOI: 10.3389/fonc.2022.912537] [Reference Citation Analysis]
6 Mao D, Xu M, Jiang Q, Sun H, Sun F, Yang R, Chai Y, Li X, Li B, Li Y. A Single Nucleotide Mixture Enhances the Antitumor Activity of Molecular-Targeted Drugs Against Hepatocellular Carcinoma. Front Pharmacol 2022;13:951831. [DOI: 10.3389/fphar.2022.951831] [Reference Citation Analysis]
7 Du F, Sun H, Sun F, Yang S, Tan H, Li X, Chai Y, Jiang Q, Han D. Knockdown of TANK-Binding Kinase 1 Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular-Targeted Drugs. Front Pharmacol 2022;13:924523. [DOI: 10.3389/fphar.2022.924523] [Reference Citation Analysis]
8 Peng Q, Hao LY, Guo YL, Zhang ZQ, Ji JM, Xue Y, Liu YW, Lu JL, Li CG, Shi XL. Solute carrier family 2 members 1 and 2 as prognostic biomarkers in hepatocellular carcinoma associated with immune infiltration. World J Clin Cases 2022; 10(13): 3989-4019 [DOI: 10.12998/wjcc.v10.i13.3989] [Reference Citation Analysis]
9 He Q, Yang J, Jin Y. Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma. Front Immunol 2022;13:869993. [PMID: 35493518 DOI: 10.3389/fimmu.2022.869993] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Tsai YT, Li CY, Huang YH, Chang TS, Lin CY, Chuang CH, Wang CY, Anuraga G, Chang TH, Shih TC, Lin ZY, Chen YL, Chung I, Lee KH, Chang CC, Sung SY, Yang KH, Tsui WL, Yap CV, Wu MH. Galectin-1 orchestrates an inflammatory tumor-stroma crosstalk in hepatoma by enhancing TNFR1 protein stability and signaling in carcinoma-associated fibroblasts. Oncogene 2022. [PMID: 35459781 DOI: 10.1038/s41388-022-02309-7] [Reference Citation Analysis]
11 Liu Z, Zhao L, Tan X, Wu Z, Zhou N, Dong N, Zhang Y, Yin T, He H, Gou J, Tang X, Gao S. Preclinical evaluations of Norcantharidin liposome and emulsion hybrid delivery system with improved encapsulation efficiency and enhanced antitumor activity. Expert Opin Drug Deliv 2022. [PMID: 35385376 DOI: 10.1080/17425247.2022.2063834] [Reference Citation Analysis]
12 He Q, Fan B, Du P, Jin Y. Construction and Validation of Two Hepatocellular Carcinoma-Progression Prognostic Scores Based on Gene Set Variation Analysis. Front Cell Dev Biol 2022;10:806989. [DOI: 10.3389/fcell.2022.806989] [Reference Citation Analysis]
13 Ishikawa N, Kamimura K, Endo S, Ishii S, Ogawa K, Sakai N, Abe H, Ko M, Shibata O, Koseki Y, Yokoyama J, Sakamaki A, Terai S. Effects of Atezolizumab and Bevacizumab on Adrenal Gland Metastasis of Hepatocellular Carcinoma: A Case Report and Review of Literature. Intern Med . [DOI: 10.2169/internalmedicine.9341-22] [Reference Citation Analysis]
14 Liu JKH, Irvine AF, Jones RL, Samson A. Immunotherapies for hepatocellular carcinoma. Cancer Med 2021. [PMID: 34953051 DOI: 10.1002/cam4.4468] [Reference Citation Analysis]
15 Park AY, Nafia I, Stringer DN, Karpiniec SS, Fitton JH. Fucoidan Independently Enhances Activity in Human Immune Cells and Has a Cytostatic Effect on Prostate Cancer Cells in the Presence of Nivolumab. Mar Drugs 2021;20:12. [PMID: 35049864 DOI: 10.3390/md20010012] [Reference Citation Analysis]
16 Gao Q, Anwar IJ, Abraham N, Barbas AS. Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors. Cancers (Basel) 2021;13:6307. [PMID: 34944927 DOI: 10.3390/cancers13246307] [Reference Citation Analysis]
17 Xing R, Gao J, Cui Q, Wang Q. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Front Immunol 2021;12:783236. [PMID: 34899747 DOI: 10.3389/fimmu.2021.783236] [Reference Citation Analysis]
18 Cai C, Yang L, Zhou K. 8DEstablishment and validation of a hypoxia-related signature predicting prognosis in hepatocellular carcinoma. BMC Gastroenterol 2021;21:463. [PMID: 34895169 DOI: 10.1186/s12876-021-02057-0] [Reference Citation Analysis]
19 Ye D, Liu Y, Li G, Sun B, Peng J, Xu Q. A New Risk Score Based on Eight Hepatocellular Carcinoma- Immune Gene Expression Can Predict the Prognosis of the Patients. Front Oncol 2021;11:766072. [PMID: 34868990 DOI: 10.3389/fonc.2021.766072] [Reference Citation Analysis]
20 Yan Y, Liang Q, Xu Z, Huang J, Chen X, Cai Y, Peng B, Yi Q. Downregulated Ferroptosis-Related Gene STEAP3 as a Novel Diagnostic and Prognostic Target for Hepatocellular Carcinoma and Its Roles in Immune Regulation. Front Cell Dev Biol 2021;9:743046. [PMID: 34790664 DOI: 10.3389/fcell.2021.743046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
21 Liu Z, Liu X, Liang J, Liu Y, Hou X, Zhang M, Li Y, Jiang X. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects. Front Immunol 2021;12:765101. [PMID: 34675942 DOI: 10.3389/fimmu.2021.765101] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Takahashi A, Umemura A, Yano K, Okishio S, Kataoka S, Okuda K, Seko Y, Yamaguchi K, Moriguchi M, Okanoue T, Itoh Y. Tyrosine Kinase Inhibitors Stimulate HLA Class I Expression by Augmenting the IFNγ/STAT1 Signaling in Hepatocellular Carcinoma Cells. Front Oncol 2021;11:707473. [PMID: 34458148 DOI: 10.3389/fonc.2021.707473] [Reference Citation Analysis]
23 Batista-Duharte A, Pera A, Aliño SF, Solana R. Regulatory T cells and vaccine effectiveness in older adults. Challenges and prospects. Int Immunopharmacol 2021;96:107761. [PMID: 34162139 DOI: 10.1016/j.intimp.2021.107761] [Reference Citation Analysis]